Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Andrew Sharabi

    TitleAssistant Clinical Professor
    SchoolUniversity of California, San Diego
    DepartmentRadiation Medicine and Applied Science
    Address9500 Gilman Drive #0843
    CA La Jolla 92093
    vCardDownload vCard

      Collapse Biography 
      Collapse Education and Training
      Johns Hopkins HospitalResidency2015Radiation Oncology
      Baylor College of MedicineM.D.2010Medicine
      Baylor College of MedicinePh.D.2009Immunology
      University of California at San DiegoB.S.2001Bioengineering
      Collapse Awards and Honors
      University of California at San Diego2017UCSD ACTRI KL2 Translational Science Award
      Johns Hopkins University2015Roentgen Resident/Fellow Research Award
      Johns Hopkins University2015American Society for Radiation Oncology (ASTRO) Travel Award
      Johns Hopkins University2014American Society for Radiation Oncology (ASTRO) Resident Clinical Basic Science Research Award
      Johns Hopkins University2013ASTRO Residents/Fellows in Radiation Oncology Research Seed Grant
      Johns Hopkins University2012John G. Rangos Medal of Honor for Creativity in Cancer Discovery
      Baylor College of Medicine20081st Place Talk, MD/PhD Program Annual Symposium
      Baylor College of Medicine20071st Place Talk, Immunology Department Annual Symposium
      Baylor College of Medicine20072nd Place Poster, Center for Cell and Gene Therapy Conference
      Baylor College of Medicine20062nd Place Poster, Immunology Department Annual Symposium
      Baylor College of Medicine20062nd Place Talk, Center for Cell and Gene Therapy Conference
      Baylor College of Medicine2003BCM M.D./Ph.D. Program Academic Achievement Award
      University of California at San Diego2001Bioengineering Department Highest Academic Achievement Award
      University of California at San Diego2001Summa Cum Laude
      University of California at San Diego2000Phi Beta Kappa National Honor Society
      University of California at San Diego 1997  - 2001Provost's Honors

      Collapse Overview 
      Collapse Overview
      Dr. Andrew Sharabi is a physician scientist and board-certified radiation oncologist at UC San Diego Moores Cancer Center. He sees patients at the La Jolla Moores Cancer Center and his specialties include Prostate (Genitourinary) and Head and Neck Cancers, as well as Skin Cancer and Thoracic Malignancies. He treats patients with novel radiotherapy techniques including intensity modulated radiotherapy (IMRT), image-guided radiotherapy (IGRT), and 4-D computed tomography, and Stereotactic Body Radiation Therapy (SBRT). Dr. Sharabi is a member and serves on the Education Committee of American Society of Therapeutic Radiology and Oncology (ASTRO) as well as National Cancer Institute (NCI) Clinical Trials Planning Committee Panels.

      Dr. Sharabi is a recognized expert on the effects of radiation on the immune system and the ability of radiation therapy to synergize with checkpoint blockade immunotherapy. He is the PI of multiple investigator initiated clinical trials combining radiation therapy with anti-PD-1 immunotherapy and has published his work in top journals including Cancer Discovery and Lancet Oncology. His laboratory in the Moores Cancer Center focuses on development of novel immunotherapies and strategies to combine radiation with immunotherapy.

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Sahebjam S, Sharabi A, Lim M, Kesarwani P, Chinnaiyan P. Immunotherapy and radiation in glioblastoma. J Neurooncol. 2017 May 31. PMID: 28567588.
        View in: PubMed
      2. Sharabi A, Kim SS, Kato S, Sanders PD, Patel SP, Sanghvi P, Weihe E, Kurzrock R. Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center. Oncologist. 2017 Jun; 22(6):631-637. PMID: 28550027.
        View in: PubMed
      3. Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. Clin Cancer Res. 2017 Mar 28. PMID: 28351930.
        View in: PubMed
      4. Green G, Carmona R, Zakeri K, Lee CH, Borgan S, Marhoon Z, Sharabi A, Mell LK. Specificity of Genetic Biomarker Studies in Cancer Research: A Systematic Review. PLoS One. 2016; 11(7):e0156489. PMID: 27383192; PMCID: PMC4934683.
      5. Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D, Kwiatkowski D, O'Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo AB, Bellmunt J, Callahan M, Cha EK, Drake C, Jarow J, Kamat A, Kim W, Knowles M, Mann B, Marchionni L, McConkey D, McShane L, Ramirez N, Sharabi A, Sharpe AH, Solit D, Tangen CM, Amiri AT, Van Allen E, West PJ, Witjes JA, Quale DZ. Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer. 2016 Apr 27; 2(2):165-202. PMID: 27376138.
        View in: PubMed
      6. Sharabi A, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015 Oct; 16(13):e498-509. PMID: 26433823.
        View in: PubMed
      7. Robertson SP, Quon H, Kiess AP, Moore JA, Yang W, Cheng Z, Afonso S, Allen M, Richardson M, Choflet A, Sharabi A, McNutt TR. A data-mining framework for large scale analysis of dose-outcome relationships in a database of irradiated head and neck cancer patients. Med Phys. 2015 Jul; 42(7):4329-37. PMID: 26133630.
        View in: PubMed
      8. Sharabi A, Tran PT, Lim M, Drake CG, Deweese TL. Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment. Oncology (Williston Park). 2015 May; 29(5):331-40. PMID: 25979541; PMCID: PMC4814161.
      9. Sharabi A, Nirschl CJ, Kochel CM, Nirschl TR, Francica BJ, Velarde E, Deweese TL, Drake CG. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen. Cancer Immunol Res. 2015 Apr; 3(4):345-55. PMID: 25527358; PMCID: PMC4390444.
      10. Raval RR, Sharabi A, Walker AJ, Drake CG, Sharma P. Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. J Immunother Cancer. 2014; 2:14. PMID: 24883190; PMCID: PMC4039332.
      11. Wild AT, Hiniker SM, Chang DT, Tran PT, Khashab MA, Limaye MR, Laheru DA, Le DT, Kumar R, Pai JS, Hargens B, Sharabi A, Shin EJ, Zheng L, Pawlik TM, Wolfgang CL, Koong AC, Herman JM. Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: experience from two institutions. J Gastrointest Oncol. 2013 Dec; 4(4):343-51. PMID: 24294505; PMCID: PMC3819776.
      12. Pinkawa M, Schoth F, Böhmer D, Hatiboglu G, Sharabi A, Song D, Eble MJ. Current standards and future directions for prostate cancer radiation therapy. Expert Rev Anticancer Ther. 2013 Jan; 13(1):75-88. PMID: 23259429.
        View in: PubMed
      13. Sharabi A, Lee SH, Goodell MA, Huang XF, Chen SY. Enhanced generation of myeloid lineages in hematopoietic differentiation from embryonic stem cells by silencing transcriptional repressor Twist-2. Cloning Stem Cells. 2009 Dec; 11(4):523-33. PMID: 20025523; PMCID: PMC2883497.
      14. Lee SH, Hong B, Sharabi A, Huang XF, Chen SY. Embryonic stem cells and mammary luminal progenitors directly sense and respond to microbial products. Stem Cells. 2009 Jul; 27(7):1604-15. PMID: 19544467; PMCID: PMC4157827.
      15. Sharabi A, Aldrich M, Sosic D, Olson EN, Friedman AD, Lee SH, Chen SY. Twist-2 controls myeloid lineage development and function. PLoS Biol. 2008 Dec 16; 6(12):e316. PMID: 19090621.
        View in: PubMed
      16. Koshikawa N, Minegishi T, Sharabi A, Quaranta V, Seiki M. Membrane-type matrix metalloproteinase-1 (MT1-MMP) is a processing enzyme for human laminin gamma 2 chain. J Biol Chem. 2005 Jan 07; 280(1):88-93. PMID: 15525652.
        View in: PubMed
      17. Bilban M, Ghaffari-Tabrizi N, Hintermann E, Bauer S, Molzer S, Zoratti C, Malli R, Sharabi A, Hiden U, Graier W, Knöfler M, Andreae F, Wagner O, Quaranta V, Desoye G. Kisspeptin-10, a KiSS-1/metastin-derived decapeptide, is a physiological invasion inhibitor of primary human trophoblasts. J Cell Sci. 2004 Mar 15; 117(Pt 8):1319-28. PMID: 15020672.
        View in: PubMed
      18. Koshikawa N, Schenk S, Moeckel G, Sharabi A, Miyazaki K, Gardner H, Zent R, Quaranta V. Proteolytic processing of laminin-5 by MT1-MMP in tissues and its effects on epithelial cell morphology. FASEB J. 2004 Feb; 18(2):364-6. PMID: 14688206.
        View in: PubMed
      19. Pirilä E, Sharabi A, Salo T, Quaranta V, Tu H, Heljasvaara R, Koshikawa N, Sorsa T, Maisi P. Matrix metalloproteinases process the laminin-5 gamma 2-chain and regulate epithelial cell migration. Biochem Biophys Res Commun. 2003 Apr 18; 303(4):1012-7. PMID: 12684035.
        View in: PubMed
      20. Hintermann E, Haake SK, Christen U, Sharabi A, Quaranta V. Discrete proteolysis of focal contact and adherens junction components in Porphyromonas gingivalis-infected oral keratinocytes: a strategy for cell adhesion and migration disabling. Infect Immun. 2002 Oct; 70(10):5846-56. PMID: 12228316; PMCID: PMC128337.
      21. Hintermann E, Bilban M, Sharabi A, Quaranta V. Inhibitory role of alpha 6 beta 4-associated erbB-2 and phosphoinositide 3-kinase in keratinocyte haptotactic migration dependent on alpha 3 beta 1 integrin. J Cell Biol. 2001 Apr 30; 153(3):465-78. PMID: 11331299; PMCID: PMC2190561.